Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Theracurmin CR-031P
- Development stage
- Preclinical
- Lead developer
- Theravalues Corp
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Theracurmin CR-031P is a highly bioavailable curcumin formulation developed by Theravalues Corporation. It utilizes submicron particle technology and colloidal dispersion (using gum ghatti) to enhance the water dispersibility and oral absorption of curcumin, a polyphenol derived from turmeric (*Curcuma longa*). This formulation reportedly achieves 18-36 times higher bioavailability than standard curcumin powder. While marketed as a dietary supplement (brand name BIHOLON in Japan), it has been investigated in clinical settings for its anti-inflammatory and antioxidant effects in conditions such as cognitive decline, common cold symptoms, and as an adjunct in cancer immunotherapy.
- Brand names
- BIHOLONTheracurmin
- Other names
- curcuminturmeric extract
02
Targets
NF-κBTNFA (Tumor necrosis factor alpha (soluble))PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Theracurmin CR-031P.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Theracurmin CR-031P.